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PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through
which oxaliplatin and ﬂuoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a
predictive factor of oxaliplatin/ﬂuoropyrimidine therapy efﬁcacy. Seventy-four metastatic colorectal cancer patients who received
oxaliplatin/ﬂoropyrimidine-based ﬁrst line therapy have been included in this retrospective study. PML expression was assessed by
immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was
signiﬁcantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P¼ 0.006).
Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P< 0.0001). A
statistical signiﬁcant difference was also detected in OS (15.6 and 24.5 months, respectively, P¼ 0.003). The impact of PML down-
regulation on TTP and OS was statistically signiﬁcant also in a multivariate model. This study represents the ﬁrst evidence of a possible
correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/
ﬂuoropyrimidine-based ﬁrst line therapy.
J. Cell. Physiol. 227: 927–933, 2012.  2011 Wiley Periodicals, Inc.
The promyelocytic leukemia (PML) gene, located at 15q22,
consists of 9 exons which encode for alternatively spliced
isoforms with both cytoplasmatic and nuclear localization. PML
nuclear isoforms (PML I, II, III, IV, V, VI) are characterized by a
nuclear location signal (NLS), coded by exon 6, which is absent
in the cytoplasmatic isoforms. The NLS allows PML localization
in the nucleoplasm or into complex protein structures known
as PML nuclear bodies (PML-NBs).
PML-NBs appear as ring-like structures composed by highly
ordered PML multimers which, together with S100 proteins,
represent the only constitutive elements of nuclear bodies. This
basic structure works as a platform on which many other
proteins are transiently recruited (Jensen et al., 2001; Shen
et al., 2006;Weidtkamp-Peters et al., 2008). The importance of
PML as tumor suppressor gene was postulated since its
identiﬁcation at the breakpoint of t(15;17) translocation, which
brings to the fusion protein PML/RARa that characterizes
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promyelocytic acute leukemia. Thanks to the interaction with
many different partners in the contest of PML-NBs, PML is able
to regulate key pathways of tumorigenesis and to control basic
cellular functions such as senescence (Chan et al., 1997;
Ferbeyre et al., 2000; Pearson et al., 2000; Mallette et al., 2004),
apoptosis (Wang et al., 1998b; Zhong et al., 2000; Salomoni
et al., 2005; Halazonetis et al., 2008), and protein synthesis
(Culjkovic et al., 2007). Furthermore, a recent work by
Bernardi et al. shows how PML regulates HIFa levels through
the interaction with mTOR. In fact, HIFa levels seem to be
higher in PML / mice, with consequently increased
neoangiogenesis and tumor vascularization (Bernardi et al.,
2006).
Despite all the previous reported evidences, a few studies up
to date evaluated the expression of PML gene in different
neoplasms. In 2004, Gurrieri et al. assessed PML expression in
human cancers of multiple histologic origins through
microarrays. They detected a partial reduction or complete
loss of PML expression in prostatic adenocarcinoma, colon
adenocarcinoma, breast cancer, lung cancer, lymphoma, CNS
tumors, and germ cells tumors (Gurrieri et al., 2004). Further
studies have shown a decreased PML expression in breast
cancer, gastric cancer, NSCLC, and invasive epithelial tumors
(Koken et al., 1995; Gambacorta et al., 1996; Zhang et al., 2000;
Lee et al., 2007).
Oxaliplatin is one of the most widely used and effective
agents in the treatment of colorectal cancer. It is a third
generation platinum drug whose two-steps activation leads to
the production of reactive compounds (Jerremalm et al., 2003)
that bound to DNA, constituting cross-links between two
adjacent guanosine residues (stable adducts). Oxaliplatin ability
of inducing DNA structural changes confers to the drug a
cytotoxic and antineoplastic action. In the treatment of
metastatic colorectal cancer (mCRC), oxaliplatin (85mg/m2
every 2 weeks) is given in association with 5-ﬂuorouracil (FU)
and folinic acid (FOLFOX) or with capecitabine (XELOX).
FOLFOX regimen has been proven to be associated with a
longer progression free survival (PFS) (9 vs. 6.2 months) and a
better response rate (RR) (50.7% vs. 22.3%) when compared
with LV5FU2 regimen in patients affected by mCRC. Although
the difference in terms of overall survival (OS) does not reach a
statistical signiﬁcance (16.2 vs. 14.7 months), FOLFOX resulted
to be signiﬁcantly superior to IFL in terms of 5-years OS (9.8%
vs. 3.7%; P¼ 0.04) (de Gramont et al., 2000). Moreover, IFL
regimen was previously shown to be associated with longer
survival when compared with LV5FU2 alone (Saltz et al., 2000).
Thus, there are currently strong evidences that FOLFOX
improves survival when compared to ﬂuoropyrimidines alone.
A study presented by Chan et al. (1997) analyzed PML
expression by immunoﬂuorescence staining in HeLa cells
treated with ionizing radiation (20Gy) and cisplatin (6mg/ml),
showing a 5–10-fold increase in PML expression. These data
underline the key role played by PML in the cellular response to
DNAdamage.However, at themoment there are no preclinical
or clinical studies demonstrating a direct link between PML and
sensitivity/resistance to oxaliplatin.
Given the possible relationship between oxaliplatin
mechanism of action and PML involvement in apoptosis, the aim
of the present study was to assess PML immunohistochemical
(IHC) expression in colorectal cancer and evaluate the value of
PML down-regulation as a predictive factor of resistance to
oxaliplatin-based therapy in mCRC patients.
Patients and Methods
The present study is retrospective, thus it was not designed in
‘‘a priori’’ model. Seventy-four consecutive (40 males and 34
females, median age 61 years) mCRC patients were included
from January 2005 to December 2006. This cohort represents
all the patients that started a ﬁrst line treatment for mCRC in
the Department of Medical Oncology at University Campus
Bio-Medico of Rome, the Unit of Medical Oncology at Hospital
of Pesaro, and the Unit of Medical Oncology 2, Azienda-
Ospedaliero Universitaria Pisana, Istituto Toscano between
January 2005 and December 2005. Inclusion criteria were only
the availability of representative tumor blocks for IHC analysis.
All tumor samples were collected at the time of surgical
resection with written informed consent. All patients received
an oxaliplatin/ﬂuoropyrimidine-based ﬁrst line regimen for
metastatic disease (FOLFOX IV and XELOX regimen in 22 and
52 patients, respectively) (Table 1). The decision to treat each
patient according to one of the two regimens was made
according to the physician’s personal decision. Treatment was
continued until the occurrence of radiologic progression as
deﬁned by RECIST criteria or the occurrence of either
unacceptable toxicity or death. There was no difference in
terms of dose intensity between patients treatedwith FOLFOX
IV and those treated with XELOX regimen (data not shown).
Tumor response was evaluated every 8 weeks by appropriate
imaging techniques (computed tomography or magnetic
resonance imaging). Assessment was performed by the
investigators on the basis of the response evaluation criteria in
solid tumors (RECIST). All the radiological tumor responses
were conﬁrmed by an independent radiological review. The
cut-off time for survival analysis was May 2009 and the median
follow-up was 28 months.
PML immunohistochemical analysis
PML expression was evaluated through immunohistochemistry
by three independent observers. Representative tumor blocks
were sectioned at 3mm thickness for IHC studies.
Immunohistochemistry was carried out by the streptoavidin-
biotin method. A mouse monoclonal antibody against PML
protein (clone PG-M3, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) was used at 1:50 dilution. This antibody has been
previously used and validated by our group and by others (Falini
TABLE 1. Baseline characteristics of the patients
Patient’s characteristics Number of patients (%)
Total number 74 (100%)
Male/female 40/34 (54/46%)
Age (years)
Median 63 years
Range 29–78 years
Performance status (ECOG)
Median 1
Range 1–2
Primary tumor site
Colon 48 (64.8%)
Rectum 26 (35.1%)
Tumor grade
G2 23 (31.0%)
G3 44 (59.5%)
G4 7 (9.5%)
No. of metastatic sites
1 31 (41.9%)
2 23 (31.1%)
3 20 (27.0%)
Sites of metastases
Liver 42 (56.7%)
Lung 25 (33.8%)
Lymph nodes 27 (36.5%)
Local 15 (20.3%)
Other 26 (35.1%)
Prior adjuvant therapy
None 25 (33.8%)
FU/LV (Mayo Clinic or De Gramont schedules) 49 (66.2%)
First line regimen
XELOX 52 (70.3%)
FOLFOX 22 (29.7%)
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et al., 1997; Mallette et al., 2004; Vincenzi et al., 2009).
DakoCytomation Labelled Streptavidin-Biotin2, Horseradish
Peroxidase (LSAB2 System, HRP, Milan, Italy) system was
utilized as staining kit. 3-3-Diaminobenzidinewas used for color
development and hematoxylin was used for counterstaining.
Negative control slides processed without primary antibody
were included for each staining. Slides were examined without
knowledge of the corresponding clinico-pathological data.
Immunostaining was considered positive if appropriate brown
staining was seen in tumor cells. PML expressionwas deﬁned by
calculating the percentage of nuclear immunoreactive cells in a
total of 1 000 neoplastic cells.
Scoring and quantiﬁcation of the immunoreactivity
PML protein expression patterns were divided into complete
loss (nuclear immunoreactivity in <10% of tumor cells), focal
positivity (in10% but<50%), and diffuse positivity (in50%),
as previously reported by Lee et al. (2007). Agreement in IHC
evaluation among the three observers was>90% (Kappa value:
0.931). In cases of disagreement, a ﬁnal score was determined
by consensus after re-examination. We compared RR and TTP
between patients with and without PML down-regulation.
MSI status determination
DNA extracted from each tumor was ampliﬁed by standard
polymerase chain reaction using microsatellite markers deﬁned
during the 1998 National Cancer Institute Workshop on
Microsatellite Instability: BAT25, BAT26, D17S250, D5S346,
ACTC, D18S55, BAT40, D10S197, BAT34c4, and MycL. In
most cases, normal control tissue was obtained from a
separate, non-tumor tissue block. When this was not possible,
non-cancer control tissue was obtained by microdissection.
Whenever necessary, microdissection was performed to
enrich tumor specimens for cancer cells, ensuring aminimumof
60% tumor within the sample. Tumors were considered MSI-
high (MSI-H) if instability was identiﬁed at 50% of the loci
screened, MSI-low (MSI-L) if at least one but 50% of the loci
showed instability, andmicrosatellite stable (MSS) if all loci were
stable. For analysis, MSI-L and MSS cases were combined (MSI-
L/S). A minimum of ﬁve successfully ampliﬁed loci were
required for classiﬁcation.
Statistical analysis
Time to progression (TTP) was calculated as the period from
the date of starting treatment to the ﬁrst observation of disease
progression or death from any cause. The duration of response
was deﬁned as the period of time from initiation of treatment
(in a patient responding to therapy) until radiological or
symptomatic disease progression. OS was calculated as the
period from the date of starting treatment until death from any
cause or until the date of the last follow-up, at which point data
were censored. TTP andOSwere determined byKaplan–Meier
product-limit method (Kaplan and Meier, 1958). The other
prognostic variables tested were: tumor grading, liver
involvement, previous adjuvant chemotherapy, albumin,
alkaline phosphatase, gamma-GT, lactate dehydrogenase
(LDH), and basal carcinoembryonic antigen (CEA) levels.
Stratiﬁed permutation tests were carried out to explore the
association between tumor response and PML expression.
Moreover, the differences in terms of TTP andOS according to
PML expression were evaluated by log-rank test. Finally, Cox
proportional hazards model was applied to the multivariate
survival analysis. Chi square testwas used to test the association
between PML expression and tumor RR. SPSS software
(version 17.00, SPSS, Chicago, IL) was used for statistical
analysis. A P value of less than 0.05 was considered to indicate
statistical signiﬁcance.
Results
PML expression
In normal colon epithelium, PML displayed a diffuse nuclear
staining pattern (Fig. 1A). Moreover, endothelial cells and
tumor-inﬁltrating lymphocytes were also strongly positive for
PML expression in both normal and tumor tissues, thus serving
as internal positive controls. In contrast, PML staining was
frequently focally or completely lost in tumor specimens.
PML down-regulation (deﬁned as either complete loss or
focal expression) was detected in 39 (52.7%) patients. In the
remaining 35 patients PML tumor expression was preserved.
In particular, 14 (18.9%) of the total 74 colon
adenocarcinoma samples were classiﬁed as PML complete loss
(Fig. 1B), and 25 (33.7%) samples as focal expression (Fig. 1C). In
the remaining 35 (47.2%) tissue samples PML was diffusely
expressed (Fig. 1D).
Correlation between PML expression and treatment
efﬁcacy
Patients with PML down-regulation showed a RR of 25.6%
versus 60.0% in patients with preserved PML expression
(P¼ 0.006). Moreover, the tumor control rate, deﬁned as the
percentage of patients who had a best-response rating of
complete response, resulted signiﬁcantly lower in those
patientswith PML down-regulation (43.6% vs. 82.8%, P¼ 0.001)
(Table 2).
Nodifferencewas identiﬁed between patientswith complete
loss or partial PML down-regulation in terms of RR and tumor
control rate.
The median TTP was 5.5 (95%CI: 2.78–7.43) months in
patients with PML down-regulation and signiﬁcantly longer in
patients without PML reduced protein expression (11.00
months, 95%CI: 6.56–14.90; P< 0.0001). Moreover, also in
terms of duration of response, PML protein expression showed
a statistically signiﬁcant impact in our cohort. OS was
signiﬁcantly different between the two groups of patients (15.60
and 24.50 months, respectively, P¼ 0.003). All these data are
summarized in Table 3 and Kaplan–Meier plots are presented in
Figure 2.
Notably, no differences in terms of efﬁcacy measurements
were detected between the group of patients treated with
FOLFOX and XELOX regimen and no difference in terms of
oxaliplatin dose-intensity was recorded according to PML
down-regulation (data not shown).
Finally, we performed survival analysis using a multivariate
model both for TTP and OS, by introducing all the clinical
variables that showed a statistical signiﬁcant impact on
prognosis in univariate analysis.
As reported in Table 4, PML maintained a statistically
signiﬁcant impact on TTP (P¼ 0.008) and OS (P¼ 0.011) in
multivariate analysis.
MSI status determination
MSI-H andMSI-Lwere observed in 19 (25.7%) and 15 (20.3%) of
the 74 primary tumors studied, respectively. For analysis, MSI-L
and MSS cases were combined and compared with the
remaining patients (with MSI) In our cohort MSI did not
correlate with efﬁcacy (RR) (P¼ 0.450) and did neither
predicted TTP nor OS (P¼ 0.951 and 0.121, respectively).
Discussion
Although there are still some enigmatic aspects in PML biology,
research in this ﬁeld has moved forward in the last few years
and produced evidences suggesting a PML tumor suppressive
function in non-hematopoietic neoplasms (Trotman et al.,
2006; Ferguson et al., 2007).
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Loss of PML expression is associated with transformation,
progression or high tumor grade in some tumors and PML has
been proven to be lost or down-regulated in many cancers of
multiple histologic origins. For example, Gurrieri et al. found
that PML gene is partially or completely lost in 31% and 17% of
colon adenocarcinomas, respectively (Gurrieri et al., 2004). In
our cohort (74 tissue samples), we observed preserved PML
expression in 47.2% of cases and partial or complete PML loss in
52.7% of patients (18.9% and 33.7%, respectively).
PML has growth suppressive and pro-apoptotic properties
and displays an altered expression pattern during human
oncogenesis (Koken et al., 1995). Its increased expression
suppresses the growth and tumorigenicity in cancer cells in vivo
and PML deﬁcient cells are resistant to apoptosis induced by
multiple stimuli (He et al., 1997; Quignon et al., 1998; Wang
et al., 1998a; Pearson et al., 2000;Wu et al., 2003). Apoptosis is
also one of the main mechanisms through which platinum
compounds, such as oxaliplatin, exert their antineoplastic
activity.
Oxaliplatin is a third-generation platinum-containing drug,
and oxaliplatin/ﬂuoropyrimidine therapy has signiﬁcantly
improved efﬁcacy compared with cisplatin-based regimens in
the treatment of colorectal cancer. The combination of
capecitabine and oxaliplatin is particularly attractive because of
its favorable tolerability proﬁle and efﬁcacy. Furthermore, it has
been shown that oral ﬂuoropyrimidines are preferred by
patients, obviating the drawbacks of prolonged intravenous
infusion. Phase III trials comparing capecitabine/oxaliplatin with
infusional regimens of 5-FU þ/ LV and oxaliplatin in mCRC
clearly point out how efﬁcacy, in terms of median PFS and OS,
and tolerability proﬁle are similar between the two regimens as
ﬁrst and second line treatment (Cassidy et al., 2004; Cassidy
et al., 2008; Rothenberg et al., 2008).
Different studies underline that oxaliplatin dose intensity is
related both to efﬁcacy and tolerability proﬁle. Oxaliplatin dose
intensiﬁcation probably improves RR and PFS in pre-treated
metastatic patients (dose below 85mg/m2 may be associated
with a worse outcome) with a slightly increased toxicity, mainly
Fig. 1. Promyelocytic leukemia (PML) protein detection by immunohistochemistry. (A) Positive PML immunostaining in peritumoral normal
epithelial cells; (B) loss of PML protein expression in colon adenocarcinoma cells (nuclear immunoreactivity in <10% of tumor cells); (C) focally
expressedPMLprotein in colon adenocarcinomacells (nuclear immunoreactivity in ‡10%but <50%); and (D) diffuse expression of PMLprotein in
colon adenocarcinoma cells (nuclear immunoreactivity in ‡50%). In all images, nuclear PML staining in endothelial cells and tissue-associated
lymphocytes represents positive control. Original magniﬁcation 400T. [Color ﬁgure can be seen in the online version of this article, available at
http://wileyonlinelibrary.com/journal/jcp]
TABLE 2. Radiological tumor response to oxaliplatin/ﬂuoropyrimidine anticancer regimen according to PML protein expression
CR (%) PR (%) SD (%) PD (%)
Down-regulated PML (39 pts) — 10 (25.6%) 7 (17.9%) 22 (56.5%)
Normally expressed PML (35 pts) 1 (2.9%) 20 (57.1%) 8 (22.9%) 6 (17.1%)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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neuropathy (Maindrault-Goebel et al., 2000, 2001). In the
OPTIMOX1 study (Tournigand et al., 2006), the ﬁrst study
evaluating the stop–start treatment strategy, previously
untreated patients were randomly assigned to receive
FOLFOX4 until progression or FOLFOX7 (oxaliplatin 130mg/
mq) for six cycles, then maintenance without oxaliplatin for
12 cycles, and reintroduction of FOLFOX7. RR was 58.5% in
arm A and 59.2% in arm B. Grade 3 sensory neuropathy was
observed in 17.9% of the patients in arm A versus 13.3% of
patients in arm B. On the contrary, in the OPTIMOX2 study
(Andre et al., 2007) oxaliplatin was administered at 100mg/mq
with signiﬁcantly lower incidence of grade 3 sensory
neuropathy (9.5%). It is noteworthy that oxaliplatin dose
intensity was not different between the groups of patients
treated with FOLOFX IV and XELOX regimen.
The identiﬁcation of predictive factors of response to
standard chemotherapy and immunotherapy in patients
affected by colorectal cancer is today a matter of strong clinical
interest. Recently, several studies pointed out how the
presence of K-Rasmutations inmCRC abrogates the efﬁcacy of
anti-EGFR therapy (Lievre et al., 2006; De Roock et al., 2008),
leading the European Medicine Agency to restrict its use to
patients with wild-type K-Ras tumors. BRAF status, EGFR
ampliﬁcation and cytoplasmic expression of PTEN seem to be
also associated with outcome in K-Ras wild-type patients
treated with a cetuximab-based regimen and they are currently
under evaluation as possible additional predictive factors
(Laurent-Puig et al., 2009). On the contrary, there is no
evidence that patients with K-Ras/BRAF mutated tumors are
less likely to beneﬁt from standard chemotherapy agents such
as irinotecan and oxaliplatin (Richman et al., 2009). Recently, a
possible link between up-regulation of the nucleotide excision
Fig. 2. Kaplan–Meier survival plots for PFS and OS in patients with normally expressed and down-regulated pml metastatic colorectal cancer
treated with oxaliplatin/ﬂuoropyrimidine-based ﬁrst line chemotherapy.
TABLE 4. Multivariate analysis for PFS and OS
Factors
Univariate Multivariate
RR 95% CI P RR 95% CI P
Progression free survival
PS (ECOG) (70–80 vs. 90–100) 1.56 1.23–1.85 0.004 1.23 0.75–1.53 0.120
Number of organs involved (1 vs. more) 0.77 0.37–0.95 0.015 0.86 0.54–0.99 0.048
PML down-regulation 0.45 0.31–0.78 <0.0001 0.67 0.34–0.81 0.008
Overall survival
PS (ECOG) (70–80 vs. 90–100) 1.98 1.23–2.07 0.002 1.56 1.18–1.99 0.009
Carcinoembryonic antigena 1.63 1.11–1.76 0.001 1.02 0.89–1.13 0.138
Number of organs involved (1 vs. more) 0.57 0.40–0.81 0.002 0.72 0.66–0.89 0.030
PML down-regulation 0.63 0.34–0.88 0.003 0.69 0.44–0.93 0.011
aContinuous variable for every 50-point CEA increase.
TABLE 3. Inﬂuence PML down-regulation on TTP, duration of response
and OS
Median TTP (95%C.I.) in months P value
TTP
Down-regulated PML 5.50 (95%CI: 2.78–7.43) <0.0001
Normally expressed PML 11.00 (95%CI: 6.56–14.90)
Duration of response
Down-regulated PML 2.8 (95%CI: 1.50–6.90) 0.006
Normally expressed PML 6.5 (95%CI: 4.40–9–20)
OS
Down-regulated PML 15.60 (95%CI: 11.30–19.50) 0.003
Normally expressed PML 24.50 (95%CI: 21.00–28.60)
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repair pathway and response to platinum-based therapy has
been supposed. In colorectal cancer, single nucleotide
polymorphism (SNP) at codon 188 of the ERCC1 resulted
associated with a reduced median survival, and it has been
suggested as a possible predictor of clinical outcome in mCRC
patients treatedwith platinum-based chemotherapy (Pare et al.,
2008). Furthermore, gene polymorphisms of EGF (Spindler
et al., 2011), EGFR and its downstream effectors (such as IL-8)
have been proposed to be associatedwith platinum compounds
sensitivity in colorectal cancer. However, further studies are
necessary to conﬁrm these initial ﬁndings (Zhang et al., 2005).
The present study provides, for the ﬁrst time, evidences
suggesting a possible correlation between PML protein
expression and outcome of mCRC patients treated with
oxaliplatin/ﬂuoropyrimidine-based ﬁrst line therapy. The link
between PML expression and efﬁcacy of oxaliplatin/
ﬂuoropyrimidine therapy has been evaluated through several
clinical parameters such as TTP, duration of response andOS. A
lower RR characterized patients with PML down-regulation
(partial or complete loss) compared to those with preserved
PML expression (25.6% vs. 60.0%, respectively), without any
signiﬁcant difference between patients with complete loss or
partial PML down-regulation. Patients with PML down-
regulation showed a signiﬁcantly shorter median TTP than
patients without reduced PML protein expression (5.5 vs. 11
months). The difference in terms of OS rate appears extremely
relevant, revealing a decreased OS time for patients with PML
down-regulated expression. All the data regarding the impact of
PML down-regulation on survival (TTP and OS) were
conﬁrmed also in multivariate analysis. In conclusion, this study
seems to support the role played by PML in cellular response to
DNA damage and the value of its down-expression as a factor
predicting resistance to oxaliplatin/ﬂuoropyrimidine therapy in
mCRC.
Nevertheless, the signiﬁcance of our study is limited by a
small sample size, absence of a validation cohort, retrospective
nature of the study itself and inability to determine prognostic
versus predictive role of PML down-regulation. In order to
conﬁrm the value of our assumptions, further larger
prospective studies appear mandatory. The identiﬁcation of a
predictive factor of resistance to oxaliplatin/ﬂuoropyrimidine
therapy, together with reliable markers of efﬁcacy, would
enable clinicians to quickly select patients most suitable for
management by this strategy.
Finally, the evaluation of PML possible involvement in the
pathogenesis of colorectal cancer (for example by assessing its
expression in normal tissue, precancerous lesion and tumor
samples) and the possible prognostic value of its down-
regulation would be of great interest.
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